Efficacy and Tolerability of Combination Antihypertensive Drug in Non-Responders to ARB monoTHerapy Using 24h ABPM

Exclusion Criteria

• •1. Secondary hypertension
• •2. SeSBP ≥ 180mmHg
• •3. SeSBP difference ≥ 20mmHg or SeDBP difference ≥ 10mmHg
• •4. A history of hypertensive encephalopathy, unstable angina, transient ischemic attack, MI, or any type of revascularization procedure within the last 6 months
• •5. Heart failure, second- or third-degree heart block, significant arrhythmia or valvular heart disease
• •6. Significant cardiovascular, cerebrovascular, renal, gastrointestinal, or hematologic disease, at the discretion of investigator
• •7. Creatinine clearance\<20mL/min and Renal artery stenosis, Renal Transplantation, Patients with only one kidney
• •8. Evidence of liver disease as indicated by alanine transaminase (ALT) and aspartate transaminase (AST) and/or total bilirubin ≥ 3 × the upper limit of normal (ULN)
• •9. Hyperkalemia (\>5.5mmol/L)
• •10. Patients with sodium depletion is not correct or Patients with fluid depletion is not correct
• •11. Chronic inflammation
• •12. Patients with severe eye-related disorders (Retinal bleeding within 6 months, Blindness, Hypertension complications with Retinal micro-aneurysms)
• •13. Diabetes mellitus
• •14. Hematologic/oncologic, neurologic and psychiatric diseases
• •15. Females who were pregnant, breastfeeding, planning a pregnancy or who were of childbearing potential
• •16. Contraindications for amlodipine, losartan, olmesartan medoxomil, or other ARBs
• •17. With known allergic reaction, lack of response or contraindication to Angiotensin II receptor antagonists
• •18. Mean DBP \> 110 mmHg
• •19. Patients who took antihyperlipidemic agents within 30 days
• •20. Subject who have participated in other clinical trial within the last one month